Enlicitide, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions Compared to Oral Non ...

A large clinical study has just reported the performance of an experimental tablet, enlicitide, capable of reducing LDL ...

Merck's experimental cholesterol buster easily outperformed a triplet of medications, the Dow Jones component said Monday.

In 1985, the Nobel Prize in Physiology or Medicine was awarded to Michael Brown and Joseph Goldstein for identifying the receptor that clears LDL particles from the bloodstream. High blood levels of ...

Study could lead to an effective new option to reduce the risk of heart attacks and strokes for millions who cannot control ...

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention ...

The trial findings complement the updated US dyslipidemia guidelines that promote early and intensive LDL lowering.

Researchers at Texas A&M Health have identified a molecular mechanism that increases cholesterol levels inside prostate ...

Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical ...

The new oral pill enlicitide cuts bad cholesterol risk by 60% in a new landmark trial. Here are the mechanisms behind it and ...